Alexion Stock Analysis

ALXN -  USA Stock  

USD 180.18  0.37  0.20%

The latest bullish price patterns experienced by current Alexion Pharm shareholders could raise concerns from institutional investors as the firm it trading at a share price of 180.18 on 510,155 in volume. The company directors and management have been very successful in rebalancing the firm assets at opportune times to take advantage of market volatility in May. The stock standard deviation of daily returns for 90 days investing horizon is currently 0.94. The very small Stock volatility is a good signal to institutional investors with longer-term investment horizons.
Please continue to Trending Equities.

Search Stock Analysis 

 
Refresh
The Alexion Pharm stock analysis report makes it easy to digest most publicly released information about Alexion Pharm and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Alexion stock analysis module also helps to analyze the Alexion Pharm price relationship with some important fundamental indicators such as market cap and management efficiency.

Alexion Stock Analysis Notes

About 90.0% of the company shares are held by institutions such as insurance companies. The book value of Alexion Pharm was presently reported as 56.21. The company has Price/Earnings To Growth (PEG) ratio of 1.46. Alexion Pharm had not issued any dividends in recent years. The entity had 2:1 split on the 23rd of May 2011. Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company was founded in 1992 and is headquartered in Boston, Massachusetts. Alexion Pharm operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 3837 people. For more info on Alexion Pharm please contact Ludwig Hantson at 475 230 2596 or go to http://www.alexion.com.

Alexion Pharm Quarterly Cost of Revenue

125.4 MillionShare

Alexion Pharm Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Alexion Pharm's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Alexion Pharm or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Alexion Pharm has a strong financial position based on the latest SEC filings
Over 90.0% of the company shares are held by institutions such as insurance companies
Latest headline from MacroaxisInsider: Payment of 928 shares by Indrani Franchini of Alexion Pharm subject to Rule 16b-3

Alexion Pharm Upcoming and Recent Events

Earnings reports are used by Alexion Pharm to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Alexion Pharm previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report29th of July 2021
Next Earnings Report4th of November 2021
Next Fiscal Quarter End30th of June 2021
Next Fiscal Year End3rd of February 2022
Last Quarter Report31st of March 2021
Last Earning Announcement30th of June 2020

Alexion Largest EPS Surprises

Earnings surprises can significantly impact Alexion Pharm's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2000-02-28
1999-12-31-0.07-0.060.0114 
1999-10-08
1999-09-30-0.08-0.09-0.0112 
1998-05-28
1998-03-31-0.08-0.070.0112 
View All Earnings Estimates

Alexion Pharm SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Alexion Pharm prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Alexion Pharm investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Alexion Pharm specific information freely available to individual and institutional investors to make a timely investment decision.
13th of May 2021
Financial Statements and Exhibits. Other Events. Submission of Matters to a Vote of Security Holders
View
11th of May 2021
Financial Statements and Exhibits. Other Events. Submission of Matters to a Vote of Security Holders
View
4th of May 2021
Other Events
View
30th of April 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
15th of March 2021
Financial Statements and Exhibits. Other Events
View
16th of February 2021
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Unclassified Corporate Event
View
12th of February 2021
Unclassified Corporate Event
View
10th of February 2021
Unclassified Corporate Event
View

Alexion Pharm Thematic Classifications

In addition to having Alexion Pharm stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Biotech IdeaBiotech
Biotechnology and pharmaceuticals production and services

Alexion Market Capitalization

The company currently falls under 'Large-Cap' category with current market capitalization of 39.9 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Alexion Pharm's market, we take the total number of its shares issued and multiply it by Alexion Pharm's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Alexion Profitablity

Alexion Pharm's profitability indicators refer to fundamental financial ratios that showcase Alexion Pharm's ability to generate income relative to its revenue or operating costs. If, let's say, Alexion Pharm is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Alexion Pharm's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Alexion Pharm's profitability requires more research than a typical breakdown of Alexion Pharm's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of 10.89 %, which can signify that it executes well on its competitive strategies and has good control over its expenditures. This is very large. Similarly, it shows Operating Margin (OM) of 52.12 %, which suggests for every 100 dollars of sales, it generated a net operating income of 0.52.
Last ReportedProjected for 2021
Return on Investment 4.41  4.53 
Return on Average Assets 0.034  0.05 
Return on Average Equity 0.05  0.07 
Return on Invested Capital 0.08  0.08 
Return on Sales 0.11  0.17 

Management Efficiency

The entity has return on total asset (ROA) of 10.08 % which means that it generated profit of $10.08 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 4.43 %, meaning that it created $4.43 on every $100 dollars invested by stockholders. Alexion Pharm management efficiency ratios could be used to measure how well alexion pharm manages its routine affairs as well as how well it operates its assets and liabilities. Return on Investment is expected to rise to 4.53 this year. Return on Average Assets is expected to rise to 0.05 this year. Alexion Pharm Return on Average Assets are quite stable at the moment as compared to the past year. The company's current value of Return on Average Assets is estimated at 0.05. Tangible Assets Book Value per Share is expected to rise to 49.02 this year, although the value of Total Assets will most likely fall to about 14.9 B.
Last ReportedProjected for 2021
Book Value per Share 52.94  44.28 
Enterprise Value over EBIT 51.00  47.55 
Enterprise Value over EBITDA 34.59  34.01 
Price to Book Value 2.94  4.23 
Tangible Assets Book Value per Share 45.44  49.02 
Enterprise Value34.7 B33.4 B
Tangible Asset Value10 B10.8 B

Technical Drivers

As of the 17th of June 2021, Alexion Pharm shows the mean deviation of 0.6868, and Risk Adjusted Performance of 0.1913. Alexion Pharm technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We have analyzed and interpolated nineteen technical drivers for Alexion Pharm, which can be compared to its rivals. Please confirm Alexion Pharm standard deviation, as well as the relationship between the maximum drawdown and expected short fall to decide if Alexion Pharm is priced correctly, providing market reflects its regular price of 180.18 per share. Given that Alexion Pharm has jensen alpha of 0.2441, we suggest you to validate Alexion Pharm's prevailing market performance to make sure the company can sustain itself at a future point.

Alexion Pharm Price Movement Analysis

The output start index for this execution was fourty-nine with a total number of output elements of twelve. The Exponential Moving Average is calculated by weighting recent values of Alexion Pharm more heavily than older values. View also all equity analysis or get more info about exponential moving average overlap studies indicator.

Alexion Pharm Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Alexion Pharm insiders, such as employees or executives, is commonly permitted as long as it does not rely on Alexion Pharm's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Alexion Pharm insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Indrani Franchini over a week ago via Macroaxis 
Payment of 928 shares by Indrani Franchini of Alexion Pharm subject to Rule 16b-3
David Brennan over three weeks ago via Macroaxis 
Acquisition by David Brennan of 1374 shares of Alexion Pharm subject to Rule 16b-3
Ludwig Hantson over two months ago via Macroaxis 
Payment of 2332 shares by Ludwig Hantson of Alexion Pharm subject to Rule 16b-3
Carino Tanisha over three months ago via Macroaxis 
Payment of 722 shares by Carino Tanisha of Alexion Pharm subject to Rule 16b-3
Bazarko Daniel over three months ago via Macroaxis 
Exercise or conversion by Bazarko Daniel of 11000 shares of Alexion Pharmaceuticals subject to Rule 16b-3
Bazarko Daniel over six months ago via Macroaxis 
Payment of 1725 shares by Bazarko Daniel of Alexion Pharmaceuticals subject to Rule 16b-3
Bazarko Daniel over six months ago via Macroaxis 
Exercise or conversion by Bazarko Daniel of 11000 shares of Alexion Pharmaceuticals subject to Rule 16b-3
Carino Tanisha over six months ago via Macroaxis 
Sale by Carino Tanisha of 1530 shares of Alexion Pharmaceuticals
Julie ONeill over six months ago via Macroaxis 
Sale by Julie ONeill of 650 shares of Alexion Pharmaceuticals
Baker Bros Advisors Lp over six months ago via Macroaxis 
Purchase by Baker Bros Advisors Lp of 2122 shares of Alexion Pharmaceuticals
Leonard Bell over a year ago via Macroaxis 
Sale by Leonard Bell of 16606 shares of Alexion Pharmaceuticals
Squinto Stephen P over a year ago via Macroaxis 
Sale by Squinto Stephen P of 1302 shares of Alexion Pharmaceuticals

Alexion Pharm Predictive Daily Indicators

Alexion Pharm intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Alexion Pharm stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Alexion Pharm Forecast Models

Alexion Pharm time-series forecasting models is one of many Alexion Pharm's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Alexion Pharm's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Alexion Pharm Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Alexion Pharm stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Alexion shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Alexion Pharm. By using and applying Alexion Stock analysis, traders can create a robust methodology for identifying Alexion entry and exit points for their positions.
Last ReportedProjected for 2021
Operating Margin 10.17  10.44 
EBITDA Margin 0.17  0.22 
Gross Margin 0.91  1.00 
Profit Margin 0.1  0.13 
Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome and SOLIRIS for the treatment of PNH, aHUS, generalized myasthenia gravis , and neuromyelitis optica spectrum disorder . It also provides Strensiq for patients with hypophosphatasia Kanuma for the treatment of patients with lysosomal acid lipase deficiency and Andexxa, a reversal agent for patients treated with rivaroxaban or apixaban. In addition, the company is developing ALXN1210 that is in Phase III clinical trials for the treatment of gMG, NMOSD, ALS, COVID-19, and HSCT-TMA ALXN1210 , which is in Phase III clinical trials for PNH and aHUS ALXN1820 that is in Phase I clinical trial, a therapeutic antagonist of properdin and ALXN1720, which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 that is in Phase III clinical trials for the treatment of Wilson disease ALXN1830, which are in Phase I clinical trials for neonatal Fc receptor ALXN2040 and ALXN2050 to treat diseases associated with dysregulation of the complement alternative pathway ALXN1850, an enzyme replacement therapy ALXN2060 for treating transthyretin amyloidosis and ALXN2075 for treatment of relapsedrefractory chronic lymphocytic leukemia. The company serves distributors, pharmacies, hospital, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc. and agreements with Dicerna Pharmaceuticals, Inc., Zealand Pharma AS, Caelum Biosciences, Inc., Stealth BioTherapeutics Corp., and Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.

Current Alexion Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Alexion analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Alexion analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
166.85Hold13Odds
Alexion Pharm current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Alexion analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Alexion stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Alexion Pharm, talking to its executives and customers, or listening to Alexion conference calls.
Alexion Analyst Advice Details

Alexion Stock Analysis Indicators

Alexion Pharm stock analysis indicators help investors evaluate how Alexion Pharm stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Alexion Pharm shares will generate the highest return on investment. By understating and applying Alexion Pharm stock analysis, traders can identify Alexion Pharm position entry and exit signals to maximize returns.
Quick Ratio3.46
Fifty Two Week Low99.91
Revenue Growth13.30%
Average Daily Volume Last 10 Day1.7M
Shares Short Prior Month7.8M
Average Daily Volume In Three Month2.13M
Earnings Growth14.40%
Shares Percent Shares Out4.05%
Earnings Quarterly Growth14.10%
Gross Margins90.94%
Forward Price Earnings12.71
Short Percent Of Float4.23%
Float Shares220.14M
Fifty Two Week High183.05
Fifty Day Average173.88
Enterprise Value To Ebitda11.24
Two Hundred Day Average157.34
Enterprise Value To Revenue5.86
Please continue to Trending Equities. Note that the Alexion Pharm information on this page should be used as a complementary analysis to other Alexion Pharm's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.

Complementary Tools for Alexion Pharm Stock analysis

When running Alexion Pharm stock analysis, check to measure Alexion Pharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alexion Pharm is operating at the current time. Most of Alexion Pharm's stock examination focuses on studying past and present price action to predict the probability of Alexion Pharm's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Alexion Pharm's price. Additionally, you may evaluate how the addition of Alexion Pharm to your portfolios can decrease your overall portfolio volatility.
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Go
Global Correlations
Find global opportunities by holding instruments from different markets
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Go
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
ETF Directory
Find actively-traded Exchange Traded Funds (ETF) from around the world
Go
The market value of Alexion Pharm is measured differently than its book value, which is the value of Alexion that is recorded on the company's balance sheet. Investors also form their own opinion of Alexion Pharm stock's value that differs from its market value or its book value, called intrinsic value, which is Alexion Pharm's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alexion Pharm's market value can be influenced by many factors that don't directly affect Alexion Pharm underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alexion Pharm's stock value and its price as these two are different measures arrived at by different means. Investors typically determine Alexion Pharm value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alexion Pharm's stock price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.